Filing Details
Vir Biotechnology, Inc. (NASDAQ:VIR) filed a Form 8-K with the Securities and Exchange Commission on July 24, 2026, disclosing a material event.
8k filedNASDAQ:VIR
Vir Biotechnology, Inc. (VIR) Reports Material Event to SEC
Filing Details Vir Biotechnology, Inc. (NASDAQ:VIR) filed a Form 8-K with the Securities and Exchange Commission on July 24, 2026, disclosing a material event. Market Context Vir…
Market Context
Vir Biotechnology, Inc.'s stock currently trades at $8.69 with a market capitalization of $923.0M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Vir Biotechnology, Inc.'s stock.
All SEC filings for Vir Biotechnology, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View VIR Stock Page
Frequently Asked Questions
Where can I read VIR's SEC filings?
Browse all filings on our VIR SEC filings page.
What types of SEC filings does Vir Biotechnology, Inc. file?
Public companies like Vir Biotechnology, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.